Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Advertisement
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Takeda And Shire - One Japan CEO's Take

The planned combination of Takeda and Shire has dominated headlines in recent weeks, but how is it viewed within the industry in Japan? One CEO shares his thoughts.
Japan Commercial

Takeda To Unlock More Cash As It Preps For Shire

Takeda is aiming to free up more cash through asset disposals to help fund its planned acquisition of Shire.
Commercial Japan

From Drinks To Drugs: DyDo Charts Course For Pharma Entry

A company with its main business in soft drinks and canned coffee might seem an unlikely entrant into the prescription pharma business, but Japan’s DyDo Group maintains it has solid reasons and a robust business plan for what it sees as an important future growth driver.

Japan Commercial

Takeda Feels Need For Speed In Approaching Shire Integration

Takeda has fleshed out several aspects of its planned acquisition of Shire, emphasizing the need for speed and decisiveness if the integration is to be successful, although investors may need more reassurance ahead of required shareholder approval. 

Japan Commercial

Takeda Grabs Shire At Last After Long Pursuit

Takeda and Shire see their £46bn combination bringing commercial and pipeline strengths across multiple therapeutic areas, along with opportunities for cost synergies and strengthening in key geographic markets. 
Japan Commercial

Takeda, Shire Finally Seal £46bn Deal

Persistence pays off for Takeda as it reaches a confirmed deal for the acquisition of Shire after a dogged pursuit, paving the way for the largest ever M&A transaction both in the Japanese pharma sector and by any Japanese company of an overseas target.

Japan M & A
See All
Advertisement
UsernamePublicRestriction

Register